

# **Implications of Recent Epidemiologic Studies for the Linear Nonthreshold Model and Radiation Protection**

*September 15, 2017*

**Note: Copyright permission is being sought for the figures and tables requiring such permission prior to their use in the final NCRP publication.**

---

National Council on Radiation Protection and Measurements  
7910 Woodmont Avenue, Suite 400, Bethesda, Maryland 20814

---

**Preface**

The National Council on Radiation Protection and Measurements (NCRP) has a long history of issuing guidance on operational radiation safety including radiation exposure limits for radiation workers and the public. Effective dose limits are based on the linear nonthreshold (LNT) dose effects model, which is based almost entirely on the human epidemiology data. This Commentary provides a review of recent epidemiologic studies and an evaluation of whether the new observations are strong enough to support or modify the LNT model as used in radiation protection today. This Report represents an update of the guidance provided in NCRP Report No.136, *Evaluation of the Linear-Nonthreshold Dose-Response Model for Ionizing Radiation* (NCRP, 2001).

This Commentary was prepared by Scientific Committee 1-25 on Recent Epidemiologic Studies and Implications for the Linear Nonthreshold Model. Serving on Scientific Committee 1-25 were:

**Roy E. Shore, Chairman**  
Radiation Effects Research Foundation, Hiroshima (retired)  
Easton, Pennsylvania

**Lawrence T. Dauer, Co-Chair**  
Memorial Sloan Kettering Cancer Center  
New York, New York

**Harold L. Beck**  
U.S. Department of Energy (retired)  
New York, New York

**Emily A. Caffrey**  
Radian Scientific  
Huntsville, Alabama

**Scott Davis**  
Fred Hutchinson Cancer Research Center  
Seattle, Washington

**Helen A. Grogan**  
Cascade Scientific  
Bend, Oregon

**Randall N. Hyer**  
Center for Risk Communication  
Philadelphia, Pennsylvania

**Fred A. Mettler, Jr.**  
University of New Mexico  
Albuquerque, New Mexico

**R. Julian Preston**  
U.S. Environmental Protection Agency (retired)  
Cary, North Carolina

**John E. Till**  
Risk Assessment Corporation  
Neeses, South Carolina

**Richard Wakeford**  
University of Manchester  
Manchester, England

**Linda Walsh**  
German Federal Office of Radiation Protection (retired)  
Germany

26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

*NCRP Secretariat*

**Richard J. Vetter**, *Staff Consultant*

**Cindy L. O'Brien**, *Managing Editor*

**Laura J. Atwell**, *Office Manager*

**Kathryn D. Held**, *Executive Director & Chief Science Officer*

The Council wishes to express its appreciation to the Committee members for the time and effort devoted to the preparation of this Commentary and to the Centers for Disease Control and Prevention and to the U.S. Nuclear Regulatory Commission for financial support.

John D. Boice, Jr.  
President

42 **Contents**

43

44 **Preface** ..... 2

45

46 **1. Executive Summary** ..... 10

47 1.1 Introduction..... 10

48 1.2 Study Reviews ..... 11

49 1.2.1 Life Span Study ..... 11

50 1.2.2 Worker Studies ..... 12

51 1.2.3 Environmental Exposure Studies ..... 13

52 1.2.4 High Background Radiation Areas ..... 13

53 1.2.5 Childhood Radiation Studies ..... 14

54 1.2.6 Diseases Classified as Tissue Reactions ..... 14

55 1.3 Results of Study Evaluations ..... 15

56 1.4 Future Improvements ..... 17

57 1.5 Summary ..... 18

58 1.6 Overall Conclusions on the Use of the LNT Model ..... 19

59

60 **2. Introduction**..... 20

61 2.1 Background ..... 20

62 2.2 LNT and the Estimation of Cancer Risk..... 22

63 2.3 Objective and Scope ..... 23

64

65 **3. Important Considerations** ..... 24

66 3.1 Epidemiologic Considerations ..... 24

67 3.2 Dosimetry Considerations..... 27

68 3.3 Statistical Considerations..... 29

69 3.4 Dose-Response Considerations..... 31

70 3.4.1 Dose Response and Solid Cancers: Cancer Type and Sensitivity ..... 31

71 3.4.2 Dose Response and Leukemia ..... 34

72 3.4.3 DDREF Considerations ..... 34

73

74 **4. Review of Epidemiologic Studies of Cancer and Genetic Effects from Low-Dose**  
75 **or Low Dose-Rate Irradiation** ..... 35

76 4.1 Japanese Atomic-Bomb Survivors..... 61

SC 1-25

Draft of September 15, 2017

110		4.2.6.2 Epidemiologic Methods, Findings and Issues .....	98
111		4.2.6.3 Study Strengths and Weaknesses.....	98
112		4.2.6.4 Implications for the LNT Model and Radiation Protection .....	99
113	4.2.7	Million Worker Study .....	99
114		4.2.7.1 Introduction.....	99
115		4.2.7.2 Dosimetry .....	100
116		4.2.7.3 Epidemiologic Methods, Findings and Issues .....	100
117		4.2.7.4 Study Strengths and Weaknesses.....	106
118		4.2.7.5 Implications for the LNT Model and Radiation Protection .....	106
119	4.2.8	Chinese Medical X-Ray Worker Study .....	106
120		4.2.8.1 Dosimetry .....	106
121		4.2.8.2 Epidemiologic Methods, Findings and Issues .....	107
122		4.2.8.3 Study Strengths and Weaknesses.....	107
123		4.2.8.4 Implications for the LNT Model and Radiation Protection .....	107
124	4.3	Environmental Exposure Studies.....	108
125	4.3.1	Techa River Resident Cohort.....	109
126		4.3.1.1 Dosimetry .....	109
127		4.3.1.2 Epidemiologic Methods, Findings and Issues .....	110
128		4.3.1.3 Study Strengths and Weaknesses.....	113
129		4.3.1.4 Implications for the LNT Model and Radiation Protection .....	113
130	4.3.2	Chernobyl Resident Cohorts.....	114
131		4.3.2.1 Dosimetry .....	114
132		4.3.2.2 Epidemiologic Methods, Findings and Issues .....	115
133		4.3.2.3 Study Strengths and Weaknesses.....	117
134		4.3.2.4 Implications for the LNT Model and Radiation Protection .....	117
135	4.3.3	High Natural Background Radiation Area (HBRA) Studies: Kerala Study .....	117
136		4.3.3.1 Dosimetry .....	118
137		4.3.3.2 Epidemiologic Methods, Findings and Issues .....	118
138		4.3.3.3 Study Strengths and Weaknesses.....	120
139		4.3.3.4 Implications for the LNT Model and Radiation Protection .....	120
140	4.3.4	Yangjiang China HBRA Study.....	121
141		4.3.4.1 Dosimetry .....	121
142		4.3.4.2 Epidemiologic Methods, Findings and Issue.....	121
143		4.2.4.3 Limitations of the Kerala and Yangjiang HBRA Studies.....	122

144	4.2.4.4	Implications of the HBRA Studies for the LNT Model and	
145		Radiation Protection .....	122
146	4.3.5	Taiwan Residents of Radiation-Contaminated Buildings.....	122
147	4.3.5.1	Dosimetry .....	122
148	4.3.5.2	Epidemiologic Methods, Findings and Issues .....	123
149	4.3.5.3	Study Strengths and Weaknesses.....	124
150	4.3.5.4	Implications for the LNT Model and Radiation Protection .....	124
151	4.3.6	Radiation Fallout Studies.....	124
152	4.3.6.1	Japanese Atomic-Bomb Fallout.....	125
153	4.3.6.2	Marshall Islands Atomic Testing Fallout.....	125
154	4.3.6.3	Nevada Test Site (NTS) Atomic Fallout in Utah.....	126
155	4.3.6.4	Atomic Testing Fallout Across the United States.....	127
156	4.3.6.5	Semipalatinsk Fallout .....	127
157	4.3.6.6	Hanford <sup>131</sup> I Fallout.....	128
158	4.3.6.7	Mayak Fallout .....	129
159	4.3.6.8	Three Mile Island (TMI) Fallout .....	129
160	4.3.6.9	Fukushima Dai-ichi Fallout .....	129
161	4.4	Medical Exposure Studies .....	130
162	4.4.1	TB Fluoroscopy Studies.....	131
163	4.4.1.1	Dosimetry .....	131
164	4.4.1.2	Epidemiologic Methods, Findings and Issues .....	132
165	4.4.1.3	Summary Studies of TB Patients Receiving Repeated Chest	
166		Fluoroscopies for Lung Collapse .....	132
167	4.4.1.4	Implications for the LNT Model and Radiation Protection .....	132
168	4.4.2	Computed Tomography Scanning Studies.....	132
169	4.4.2.1	Dosimetry .....	133
170	4.4.2.2	Epidemiologic Methods, Findings and Issues .....	133
171	4.4.2.3	Strengths and Limitations .....	134
172	4.4.2.4	Analyses to Evaluate Biases in CT Studies .....	135
173	4.4.2.5	Implications for the LNT Model and Radiation Protection .....	135
174	4.5	Childhood Exposure Studies .....	136
175	4.5.1	Childhood Atomic-Bomb Survivors.....	137
176	4.5.2	Childhood Leukemia Studies.....	137
177	4.5.3	Thyroid Cancer Studies .....	138

178	4.5.3.1	Pooled Studies of Thyroid Cancer after X- or Gamma Irradiation .....	138
179	4.5.3.2	Other Studies of Thyroid Cancer after Childhood Exposure.....	142
180	4.5.4	Breast Cancer Studies .....	142
181	4.6	<i>In Utero</i> Exposure Studies .....	143
182	4.6.1	Pregnancy Risks from Ionizing Radiation .....	144
183	4.6.2	<i>In Utero</i> Exposures to Occupational or Environmental Sources .....	144
184	4.6.3	<i>In Utero</i> Diagnostic Radiology.....	146
185	4.7	Genetic Studies (Heritable Effects in Human Populations).....	147
186	4.7.1	Studies of Atomic-Bomb Survivor Offspring.....	147
187	4.7.2	Studies of Offspring after Parental Preconception Radiotherapy .....	148
188	4.7.3	Cancer in Offspring after Environmental Preconception Radiation	
189		Exposure .....	149
190	4.7.4	Implications for Radiation Protection.....	149
191			
192	<b>5.</b>	<b>Review of Epidemiologic Studies for Tissue Reactions .....</b>	<b>150</b>
193	5.1	Cardiovascular Effects Studies .....	151
194	5.1.1	Higher Doses and Cardiovascular Disease .....	152
195	5.1.2	TB Fluoroscopy Studies.....	153
196	5.1.2.1	Dosimetry .....	153
197	5.1.2.2	Study Strengths and Weaknesses.....	153
198	5.1.2.3	Implications for the LNT Model and Radiation Protection .....	154
199	5.1.3	Nuclear Worker Radiation Exposure and Cardiovascular Diseases .....	154
200	5.1.4	Environmental Radiation Exposure .....	160
201	5.1.5	Implications of Cardiovascular Disease for the LNT Model and Radiation	
202		Protection.....	160
203	5.2	Cataract Studies .....	162
204	5.3	Thyroid Noncancer Effects Studies .....	162
205	5.3.1	Atomic-Bomb Studies.....	163
206	5.3.2	Chernobyl <sup>131</sup> I Fallout and Noncancer Thyroid Effects.....	163
207	5.3.3	Other Studies of Radioactive Iodine Fallout and Thyroid Effects.....	163
208	5.3.4	Implications of Noncancer Thyroid Effects for Radiation Protection .....	164
209			
210	<b>6.</b>	<b>Study Quality.....</b>	<b>165</b>
211	6.1	Strengths .....	165

212           6.2    Opportunities for Improvement ..... 166

213

214   **7.    Strength of Support for LNT in Recent Epidemiologic Studies ..... 167**

215

216   **8.    Future Directions ..... 171**

217           8.1    Epidemiology ..... 171

218                 8.1.1   Atomic-Bomb Studies..... 171

219                 8.1.2   Radiation Worker Studies..... 173

220                 8.1.3   Environmental Radiation Studies ..... 173

221                 8.1.4   Computed Tomography Studies ..... 174

222                 8.1.5   Childhood and *In Utero* Exposures..... 174

223                 8.1.6   Studies of Tissue Reactions ..... 175

224           8.2    Dosimetry: Future Directions ..... 175

225           8.3    DDREF: Future Directions ..... 176

226           8.4    Key Events, Bioindicators and Risk Assessment: Future Directions ..... 177

227           8.5    Other Future Directions/Recommendations ..... 178

228

229   **9.    Conclusions ..... 180**

230           9.1    Overall Conclusion on Use of the LNT Model..... 180

231           9.2    Supporting Conclusions ..... 180

232           9.3    Radiation Protection Implications..... 181

233

234   **Glossary ..... 182**

235

236   **Abbreviations, Acronyms and Symbols ..... 187**

237

238   **References ..... 189**

239

240 **1. Executive Summary**

241

242

**1.1 Introduction**

243

244 Historically, epidemiologic studies have assessed the health effects of ionizing radiation exposure from multiple  
245 sources: occupational, accidental, environmental, military and medical. The several national and international  
246 reviews of the status of health risks associated with exposure to low levels of ionizing radiation that have been  
247 completed in the last few decades generally agreed that the expectations for health effects in humans, such as cancer  
248 induction or cardiac damage, observed at acute doses of 100 mGy and above are more reliable than those observed  
249 at <100 mGy, the low-dose region (NCRP, 2015). For the purpose of this Commentary, for low linear-energy  
250 transfer (LET) radiation, a low absorbed dose is <100 mGy delivered acutely, and a low absorbed-dose rate is  
251 <5 mGy h<sup>-1</sup> for any accumulated dose. See NCRP Commentary No. 24 (NCRP, 2015) Section 1.1 for additional  
252 discussion of low doses and low dose rates.

253

254 Our understanding of the shape of the dose-response relationship and the level of risk from low-LET types of  
255 radiation at low doses and low dose rates remains uncertain because of the intrinsic uncertainties in results from the  
256 epidemiologic and radiobiological studies of low doses of radiation. This uncertainty can impact actions taken  
257 regarding radiation protection guidance, medical practice, compensation programs, environmental contamination  
258 issues, technological advances, and communication with members of the public (NCRP, 2015). For over 40 y the  
259 linear nonthreshold (LNT) dose-response model has been commonly utilized for low-LET radiation when  
260 developing practical and prudent guidance on ways to protect workers and the public from the potential for harmful  
261 effects from radiation while balancing the beneficial, justified, and optimized uses of radiation in our society.  
262 Indeed, in developing its basic recommendations, as currently given in NCRP Report No. 116 (NCRP, 1993a), the  
263 Council reiterated its acceptance of the LNT model for the purposes of radiation protection.

264

265 The purpose of this Commentary is to provide a review of recent data from studies with low dose rates and from  
266 the Life Span Study of atomic-bomb survivors to determine whether these epidemiologic studies broadly support the  
267 LNT model of carcinogenic risk or, on the contrary, whether there is sufficient evidence that the LNT model is  
268 inappropriate for the purposes of radiation protection. The strength of epidemiologic support for the LNT model is  
269 evaluated for solid cancer incidence or mortality and secondarily for low dose-rate studies of leukemia. Briefer  
270 consideration is also given to low dose studies of thyroid cancer and breast cancer. The focus of this commentary is  
271 on low doses and low dose rates.

272

273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306

## 1.2 Study Reviews

The primary approach was a critical review of each major study. The critique included an assessment of the quality of the epidemiology, dosimetry, and statistics of each study. The epidemiologic evaluation included a characterization of the study design and study population, quality of the data available, data collection methodology, the degree to which potential confounding variables or biases were assessed, and the quantitative results. Analysis of the dosimetry helped evaluate the robustness of the study in supporting the shape of the dose response curve at low doses and low dose rates. A statistical evaluation considered whether the analytic methods were appropriate, whether the study considered statistical alternatives to a linear dose-response trend, and whether sensitivity analyses or other clarifying analyses were undertaken. Based on those considerations, the contribution the study makes to the LNT model and to radiation protection is characterized. Several key studies about solid cancer mortality or incidence are briefly summarized below.

### 1.2.1 *Life Span Study*

Although this report focuses on studies with low doses and low dose rates, the Life Span Study (LSS) was included as a benchmark comparison study. The LSS cohort of atomic-bomb survivors (Section 4.1) has provided important data because it is a large cohort (~86,000 survivors of all ages) with relatively accurate dosimetry, a wide dose range (0 to 4 Gy colon dose, including ~68,000 with doses <100 mGy), over 50 y of high-quality follow-up for mortality and cancer incidence, and over 1,000 excess cancer cases associated with radiation exposure. These features provide relatively high statistical power and precision of risk estimates, resulting in a statistically significant dose response for all incident solid cancer over the dose range 0 to 100 mGy (Grant *et al.*, 2017). Formal dose-threshold analyses for both solid cancer incidence and mortality are compatible with no dose threshold, and a pure quadratic model provided a significantly poorer fit than a linear dose-response model (Grant *et al.*, 2017; Ozasa *et al.*, 2012).

A nonparametric analysis of the most recent mortality data indicated excess risk over the range of 0 to 200 mGy that was congruent with the LNT dose response model. Nevertheless, the most recent solid cancer mortality and incidence data provide some evidence for upward curvature in the dose response consistent with a linear-quadratic model. This implies a shallower, but still positive, dose-response slope at low doses than at higher ones, though this curvilinearity appeared to be confined primarily to males. In summary, the study provides strong support for the use of a LNT model, with consideration of a low-dose effectiveness factor (LDEF), for use in radiation protection. However, unlike most other studies reviewed in this report, the LSS assesses the effects of a single, brief exposure and the associated LDEF, but it does not assess protracted or highly-fractionated doses.

307

308 **1.2.2** *Worker Studies*

309

310 Radiation worker studies assess risks in worker groups exposed largely to low doses received at low dose-rates,  
311 addressing directly the validity of the LNT model for low dose-rate exposures. Further, cumulative doses can be  
312 several hundred mGy, especially for workers in early periods, so that some studies can offer reasonable statistical  
313 power.

314

315 **INWORKS Study:** Large studies that combine data from workers from numerous nuclear installations in a number  
316 of countries have now been conducted (Cardis *et al.*, 1995; 2007). An important study is the International Nuclear  
317 Workers Study (INWORKS), which included workers from nuclear facilities in the United States, United Kingdom,  
318 and France (Leuraud *et al.*, 2015; Hamra *et al.*, 2016; Richardson *et al.*, 2015) (reviewed in Section 4.2.2).

319 INWORKS found an association between the cumulative external photon dose to the red bone marrow (RBM) and  
320 mortality from leukemia [excluding chronic lymphocytic leukemia (CLL) excess relative risk (ERR) Gy<sup>-1</sup> of 3.0,  
321 90 % confidence interval (CI) of 1.2 to 5.2]. External dose to the colon (used as the prototypic organ) was associated  
322 with mortality from all solid cancers combined (ERR Gy<sup>-1</sup> of 0.47, 90 % CI of 0.18 to 0.78). For solid cancer there  
323 was no evidence of nonlinearity ( $p = 0.44$ ). These risk estimates were similar to those in the LSS data. Even when  
324 the cumulative colon dose was restricted to 0 to 100 mGy, a statistically significant dose response was seen for all  
325 cancers excluding leukemia.

326

327 **Mayak Study:** The Russian Mayak workforce is of particular interest because of the high cumulative doses  
328 received (mainly at a low dose rate) by many workers during the early years of operations at this installation  
329 (Section 4.2.3). The investigators reported statistically significant associations between external dose and mortality  
330 from leukemia (excluding CLL) and from all solid cancers excluding lung, liver and bone (*i.e.*, excluding cancers at  
331 the major sites of plutonium deposition); and adjusting for plutonium exposure; ERR Gy<sup>-1</sup> of 0.12, 95 % CI: 0.03 to  
332 0.21 (Sokolnikov *et al.*, 2015). For solid cancer there was no indication of nonlinearity ( $p > 0.5$ ) based on external  
333 dose to the colon. For leukemia, excluding the chronic lymphocytic type, the linear ERR Gy<sup>-1</sup> estimate was 3.57  
334 (90 % CI 1.55, 8.22) for cumulative external radiation dose to the red bone marrow, adjusted for plutonium  
335 exposure. The linear-quadratic model fit marginally better than the linear model ( $p = 0.11$ ), and the pure linear and  
336 pure quadratic models fit about equally well.

337

338 **Summary of Worker Studies:** Overall the nuclear worker studies lend considerable support to the inference that an  
339 excess risk of cancer exists following protracted exposure to low doses received at a low dose rate, and the excess  
340 risk is compatible with a LNT model, perhaps modified by a DDREF. Although the accuracy of the risk estimates is

341 limited to some degree by uncertainties in dosimetry and epidemiology, the studies provide substantial support for  
342 the LNT model. The Million Worker Study is underway in the United States; when it is completed it is expected to  
343 augment appreciably the information available on worker radiation-related cancer risks and reduce the uncertainties  
344 in risk estimation after exposures at low dose rates (Boice, 2015a; 2017c; Boice *et al.*, 2014; Bouville *et al.*, 2015;  
345 Till *et al.*, 2014).

346

### 347 1.2.3 *Environmental Exposure Studies*

348

349 **Techa River Study:** Between 1949 and 1956 the Russian Mayak nuclear weapons facility released radioactive  
350 waste into the Techa River and exposed approximately 30,000 residents to relatively low doses at low dose rates  
351 from gamma rays (external) and  $^{137}\text{Cs}$  and  $^{90}\text{Sr}$  (internal). The recent studies of the Techa River Cohort have found  
352 associations between radiation dose and incidence and mortality rates for solid cancers and leukemia (other than  
353 CLL) that they report are linear in dose response (Davis *et al.*, 2015; Krestinina *et al.*, 2013a; Schonfeld *et al.*, 2013)  
354 (Section 4.3.1). However, inherent uncertainties in the dose reconstruction along with some limitation in the cancer  
355 ascertainment weaken inferences about the shape of the dose-response curves and the LNT model.

356

357 **Chernobyl Thyroid Cancer Studies:** New studies of cohorts of children in Ukraine and Belarus who had thyroid  
358 measurements of  $^{131}\text{I}$  shortly after the Chernobyl accident and systematic thyroid screening have added appreciably  
359 to our knowledge about thyroid cancer risk after protracted internal exposure (Brenner *et al.*, 2011; Zablotska *et al.*,  
360 2011) (Section 4.3.2). Both cohorts showed strong linear dose-response functions with no evidence of nonlinearity,  
361 though perhaps with a somewhat lower risk per unit dose than seen in studies of children exposed to external  
362 gamma radiation. The thyroid doses are believed to be sufficiently accurate to support a LNT interpretation.

363

### 364 1.2.4 *High Background Radiation Areas*

365

366 Studies of residents in areas of high natural background radiation have been conducted in Kerala, India and  
367 Yangjiang, China. However, it is exceedingly difficult to conduct a geographic study of background radiation, *e.g.*,  
368 it is difficult to find a suitable low exposure control group with highly similar lifestyles and natural disease rates to  
369 whom the highly exposed group may be compared. The better and larger of the two studies, the Kerala study of  
370 cancer incidence, included 70,000 individuals and over 1,300 cancers from high-background or low-background  
371 areas (Nair *et al.*, 2009) (Section 4.3.3). The dosimetry was based on measurements of ambient levels within and  
372 near homes, coupled with average house-occupancy factors by age and sex. They reported an ERR  $\text{Gy}^{-1}$  of  $-0.13$   
373 (95 % CI  $-0.58, 0.46$ ) for all cancer except leukemia, and there were too few leukemia cases to be informative. The  
374 Yangjiang study reported a positive, but nonsignificant, risk coefficient for all cancer except leukemia and liver

375 cancer [ERR Gy<sup>-1</sup> 0.19 (95 % CI -1.9, 3.0); Tao *et al.*, 2012]. These studies are nominally more supportive of little  
376 or no effect after low dose-rate exposures rather than the LNT model. However, the fact that much of the dose  
377 variation is attributable to geographic locations, which may be associated with risk factors other than radiation level,  
378 introduces ambiguity into the inference regarding radiation effects. Furthermore, the substantial uncertainties in  
379 dosimetry, the weaknesses in cancer ascertainment, and the wide confidence intervals on the risk estimates mean  
380 they need to be interpreted with caution.

381

### 382 **1.2.5** *Childhood Radiation Studies*

383

384 Medical exposures are typically partial body and study results are subject to significant uncertainties including,  
385 but not limited to, historical exposure data, limited organ dosimetry for organs other than the target organ, and  
386 potential biases because radiologic procedures are often administered for an existing health condition. Recent  
387 epidemiologic studies have involved populations who had received computed tomography (CT) scans during  
388 childhood when risk might be greater because CT doses were relatively high and children may be more  
389 radiosensitive to cancer induction than adults (Section 4.4.2). However, information on organ doses from CT  
390 examinations in the 1980s and 1990s is sparse and individual doses have not been reconstructed. CT studies suffer  
391 from potential biases: confounding by indication (CT examinations more likely for those who have conditions that  
392 confer risk for cancer) and reverse causation (pre-existing but undetected malignancy). Because of the weak  
393 dosimetry and potential for bias, the results are considered unreliable for evaluating the LNT dose response model.

394

395 The data on postnatal diagnostic medical exposures and childhood leukemia risk are inconclusive (Wakeford,  
396 2008). Studies of juvenile irradiation and breast cancer generally support a linear dose response. A recent pooled  
397 analysis of external thyroid irradiation in childhood and subsequent thyroid cancer in nine studies showed a  
398 significant dose response from 0 to 100 mGy and no evidence of nonlinearity (Lubin *et al.*, 2017). An analysis of  
399 solid cancer incidence among the Japanese atomic-bomb survivors exposed prenatally or during childhood showed a  
400 clear dose response, but marginal upward curvature ( $p = 0.09$ ) suggested that the dose-response slope may be  
401 shallower in the low-dose range. In general, the low dose data on children are sparse, the number of specific types of  
402 cancer is small and uncertainties are large enough that such studies do not yield definitive information on the LNT  
403 model. In the case of thyroid cancer and breast cancer, the data broadly support the LNT model.

404

### 405 **1.2.6** *Diseases Classified as Tissue Reactions*

406

407 Most of the available data on noncancer effects have large associated uncertainties and limitations that do not  
408 yet support a quantitative estimate of a specific threshold value for effects from either acute or protracted lens

409 exposures. However, the preponderance of evidence suggests the possibility that effects (such as lens opacities or  
410 cardiovascular disease) could occur at lower doses than previously thought.

411  
412 There is growing epidemiologic evidence to suggest a raised risk of cardiovascular disease (CVD) at lower  
413 levels of exposure to radiation than previously thought, implying that poorly understood radiobiological  
414 mechanisms associated with low-to-moderate doses and/or low dose rates may produce an increased risk of CVD  
415 (Section 5.1). Studies of nuclear workers and other exposed groups provide a mixed picture as to CVD risk, and  
416 most of them lack information on important confounding factors associated with lifestyle and concurrent conditions  
417 (*e.g.*, diabetes, obesity). Therefore, the evidence is too weak and inconsistent to support a LNT model for CVD at  
418 this time.

419  
420 Studies of cataracts in the atomic-bomb survivors and following Chernobyl exposures have revealed the  
421 development of minor lenticular opacities at doses lower than previously considered to be cataractogenic.  
422 Ophthalmologically detectable opacities are reported at doses of 0.5 to 2 Gy with large uncertainties below about  
423 0.5 Gy. So, at this time, the NCRP recommends use of a threshold model for cataracts (NCRP, 2016).

424

### 425 **1.3 Results of Study Evaluations**

426

427 Support by studies for any model requires adequacy of the study components, which for epidemiologic studies  
428 can be classified broadly as adequacy of epidemiologic methods, dosimetry, and statistics. For each component of  
429 the major studies, this commentary has critiqued both the methods used and the adequacy of the results of those  
430 methods (Section 7). The Committee evaluated these components for 26 principal studies or groups of studies of  
431 cancer risk. As a minimal criterion of study adequacy, 18 of the studies had no component on which they were  
432 scored as weak. Thirteen of the studies were scored moderate to strong on all three components of evaluation.

433

434 The Committee also rated each study or group of studies on their strength of support for the LNT model, as  
435 shown in Table 1.1. Twenty-one studies (80 %) provided some support for the LNT model, including five studies  
436 (19 %) providing strong support and seven providing moderate support.. Five of the studies (19 %) provided  
437 essentially no or inconclusive support for the LNT model. A rating of moderate versus strong support for LNT  
438 sometimes hinged upon the size of the study or other limitation and not on indications of nonlinearity. most of the  
439 larger,

Table 1.1—Ratings of the degree of support for the LNT model by the cancer studies reviewed.

Study (or groups of studies) a	Support for LNT Model
Life Span Study (LSS), Japan atomic bomb (Grant <i>et al.</i> , 2017) <sup>b</sup>	Strong
INWORKS (U.K., U.S., French combined cohorts) (Richardson <i>et al.</i> , 2015)	Strong
Tuberculosis fluoroscopic examinations and breast cancer (Little and Boice, 2003)	Strong
Childhood atomic-bomb exposure (Preston <i>et al.</i> , 2008)	Strong
Childhood thyroid cancer studies (Lubin <i>et al.</i> , 2017)	Strong
Mayak nuclear facility (Sokolnikov <i>et al.</i> , 2015)	Moderate
Techa River, nearby residents Davis <i>et al.</i> , 2015)	Moderate
Chernobyl fallout, Ukraine and Belarus thyroid cancer (Brenner <i>et al.</i> , 2011)	Moderate
Breast cancer studies, after childhood exposure (Eidemüller <i>et al.</i> , 2015)	Moderate
<i>In utero</i> atomic-bomb exposure (Preston <i>et al.</i> , 2008)	Moderate
<i>In utero</i> exposures, medical (Wakeford, 2008)	Moderate
Canadian worker study (Zablotska <i>et al.</i> , 2013b)	Moderate
Japanese worker study (Akiba and Mizuno, 2012)	Weak to moderate
Chernobyl cleanup workers, Russia (Kashcheev <i>et al.</i> , 2015)	Weak to moderate
U.S. radiologic technologists (Liu <i>et al.</i> , 2014; Preston <i>et al.</i> , 2016)	Weak-to-moderate
Mound facility (Boice <i>et al.</i> , 2014)	Weak-to-moderate
Rocketdyne facility (Boice <i>et al.</i> , 2011)	Weak-to-moderate
Medical x-ray workers, China (Sun <i>et al.</i> , 2016)	Weak-to-moderate
Background radiation levels and childhood leukemia (Kendall <i>et al.</i> , 2013)	Weak-to-moderate
Taiwan radiocontaminated buildings, residents (Hwang <i>et al.</i> , 2008)	Weak-to-moderate <sup>c</sup>
Pediatric CT examinations (Pearce <i>et al.</i> , 2012)	Weak-to-moderate <sup>c</sup>
Childhood leukemia studies (Wakeford and Little, 2003)	Weak-to-moderate
<i>In utero</i> exposures, Mayak and Techa (Akleyev <i>et al.</i> , 2016)	Weak-to-moderate
Hanford <sup>131</sup> I fallout study (Davis <i>et al.</i> , 2004)	None
Kerala, India, high natural background radiation area (Nair <i>et al.</i> , 2009)	None
Yangjiang, China, high natural background radiation area (Tao <i>et al.</i> , 2012)	Inconclusive <sup>c</sup>
U.S. atomic veterans (Beck <i>et al.</i> , 2017)	Inconclusive
Fallout studies (aggregate of eight studies) (Lyon <i>et al.</i> , 2006)	Inconclusive <sup>c</sup>

<sup>a</sup>A number of studies were excluded for various reasons described in the text, these include but are not limited to: ecological studies of residents around nuclear power plant facilities, studies of hereditary effects, studies of tissue reaction (or “deterministic”) effects, and the 15-country study

<sup>b</sup>A representative recent publication is listed for each study or study group.

<sup>c</sup>Considered “weak” support or “inconclusive” primarily because of epidemiologic method or dosimetric weaknesses. The other studies in these categories were reasonable methodologically but provided little or no support for the LNT model because their risk coefficients were essentially zero or negative.

440 stronger studies broadly supported a LNT model. The studies that provided no support for the LNT model either  
441 had a totally null dose response or had excessively unreliable data. It should be noted that all the studies being  
442 considered, except for the Life Span Study of atomic-bomb survivors, had exposures at low dose rates or multiple  
443 small exposures. Furthermore, the preponderance of study subjects had cumulative doses under 100 mGy. Thus  
444 these studies are very relevant for contemporary radiation protection concerns.

445

#### 446 **1.4 Future Improvements**

447

448 To stimulate radiation epidemiology efforts to address the LNT model and low- dose risks, the Committee  
449 suggested a number of profitable areas of focus for future research (report Section 8), and a few are mentioned  
450 here.

451

452 **Atomic-Bomb Survivors:** The low-dose data need to be examined in more detail, using additional covariables,  
453 statistical methods and analytic strategies, not only for solid cancer and leukemia, but also to evaluate specific  
454 cancers or cancer groups, cardiovascular diseases, and various clinical health endpoints. An examination is needed  
455 of whether the dose-response LNT model applies to tumors of various organs or organ systems, insofar as  
456 statistical limitations permit, which will provide evidence regarding the generality of the LNT model across tumor  
457 sites. The large bank of blood and tissue samples should be studied more robustly by the biomedical community to  
458 identify bioindicators of drivers of adverse outcome pathways that mediate between radiation and disease  
459 development.

460

461 **Worker Studies:** Much of the statistical power of these studies derives from those workers who have  
462 accumulated moderate doses of several hundred milligray over many years, most of whom started work in earlier  
463 years. Continuing follow-up of worker cohorts is desirable, as much of the cancer incidence and mortality is yet to  
464 occur. Doses in the early years tended to be highest but also had the greatest uncertainties because most dose  
465 recording technologies and dose record keeping practices were less advanced. Therefore, scrutiny of dose records  
466 is necessary to identify any deficiencies in recorded doses. Issues of neutron exposures, internal exposures and  
467 missing doses need to be addressed further. Valid risk estimates depend, inter alia, upon reliable dose estimates, so  
468 this area should be pursued vigorously.

469

470 **Environmental Radiation Studies:** All the environmental study groups should consider measures to reduce  
471 individual dose uncertainties. The Kerala and Yangjiang studies should increase efforts to improve cancer  
472 ascertainment and diagnosis, and to closely examine sociodemographic and geographic factors that may affect the

473 adequacy of cancer ascertainment. Further validation of reconstructed doses by personal dosimetry measurements  
474 would also be valuable. The Techa River studies should continue to improve dosimetry, enhance their follow-up  
475 and outcome ascertainment and further address the medical exposures received.

476  
477 **Other Future Directions:** Uncertainties should be provided with the dose estimates and used to adjust risk  
478 coefficients and confidence intervals (Stram *et al.*, 2015; UNSCEAR, 2015). For radiation-induced adverse health  
479 outcomes, a clear need is to identify bioindicators that define the pathway from normal to malignant cells that can  
480 be used for developing biologically based dose-response models. Analyzing epidemiologic data in conjunction with  
481 relevant radiobiological concepts and data has the potential to provide insights about low-dose risk that augment  
482 knowledge gained from the empirical epidemiologic data in isolation (NCRP, 2015).

483

### 484 1.5 Summary

485

486 Quantitative solid cancer risk estimates, based on estimated individual doses, of cancer mortality or incidence  
487 have been reported for nearly one million individuals with low dose rates and mostly low doses from studies of  
488 radiation workers or those exposed to elevated environmental radiation levels (Shore *et al.*, 2017). The completion  
489 of the million person study will considerably augment the available information (Boice, 2012a). The more robust  
490 studies have many strengths, with relatively good quality dosimetry, high rates of cohort mortality/morbidity  
491 ascertainment, attention to potential confounding variables, and proper analysis. Nevertheless, it is recognized that  
492 all studies have limitations, ranging from minor to serious, in their contribution to the quantitative evaluation of  
493 the LNT model. The individual low- dose studies intrinsically have limited statistical power and precision in risk  
494 estimation. These studies complement the LSS study of atomic-bomb survivors with its high dose rate and high  
495 dose range.

496

497 Strengths of some of the large epidemiologic studies such as INWORKS and the LSS lie in the long follow-up  
498 and large numbers of cancers and person-years at risk. The length of follow-up of epidemiologic studies is  
499 particularly relevant since a large fraction of both spontaneous and radiation-related cancers occur at 60 y of age  
500 and beyond. Although an historic weakness of many worker and environmental radiation studies was inadequate  
501 dosimetry, in recent years investigators have been focusing more on improving the quality and accuracy of the  
502 dosimetry. However, most studies considered in this report did not consider the effects of shared vs unshared  
503 uncertainty and classical as opposed to Berkson error (UNSCEAR, 2015), and then adjust for the effects of dose  
504 uncertainty on the risk estimates. Nearly all studies have adjusted for potential confounding by sex, attained age  
505 and sometimes age at exposure. However, few studies have analyzed radiation risks with control for possible  
506 confounding by lifestyle (*e.g.*, smoking), other disease risk factors or other sources of radiation exposure; these

507 factors may diminish the consistency of findings. Nevertheless, it should be emphasized that lifestyle or other  
508 disease risk factors will cause confounding only if their frequency (or intensity) varies appreciably according to  
509 dose. The most prominent lifestyle risk factor is smoking. Adjustment for socioeconomic status is used in several  
510 studies as an indirect approach for controlling for smoking and other lifestyle factors. Indirect approaches to  
511 examine the impact of smoking in several major studies have not found that smoking introduced substantial bias  
512 (Akiba, 2013; Davis *et al.*, 2015; Hunter *et al.*, 2013; Richardson *et al.*, 2015). For a few studies, concomitant  
513 medical radiation exposures have been examined; for the Techa River study diagnostic medical exposures at the  
514 official clinic were included in the doses (Schonfeld *et al.*, 2013). Other factors, such as losses to follow-up or  
515 incomplete disease ascertainment, would cause bias in the risk estimates only if they occur differentially according  
516 to dose levels. Few studies currently have biological samples to evaluate genetic or phenotypic biological factors  
517 that might cause effect modification of radiation risks.

518  
519 Because individual studies with low doses (less than 100 mGy) almost inevitably have relatively low statistical  
520 power, the findings for radiation and solid cancer are often not statistically significant. Furthermore, studies may  
521 have sampling variation or confounding by other exposures (*e.g.*, smoking or other lifestyle factors) which can  
522 diminish the consistency or validity of findings. Nevertheless, most large and high quality low- dose studies show  
523 positive risk coefficients (Shore *et al.*, 2017), suggesting there may be cancer effects at low doses, which is  
524 consistent with, though not necessarily proving, the applicability of the LNT model for radiation protection.  
525 However, it should be recognized that, the risk of cancer at low doses is small.

526  
527 The data regarding noncancer effects at low doses—cardiovascular diseases, cataracts, thyroid dysfunction,  
528 central nervous system effects—are mixed or null, suggesting at this time that an LNT assumption for radiation  
529 protection purposes for noncancer effects is not appropriate.

530

531

## 1.6 Overall Conclusions on the Use of the LNT Model

532

533 While the ongoing development of science requires a constant reassessment of prior and emerging evidence to  
534 assure that the approach to radiation protection is optimal, though not necessarily perfect, NCRP concludes that,  
535 based on current epidemiologic data, the LNT model (perhaps modified by a DDREF) should continue to be  
536 utilized for radiation protection purposes. This is in accord with judgment by other national and international  
537 scientific committees, based on somewhat older data than in the present report (ICRP, 2007; NA/NRC, 2006;  
538 UNSCEAR, 2008), that no alternative dose-response relationship appears more pragmatic or prudent for radiation  
539 protection purposes than the LNT model.

540

541 **2. Introduction**

542

543

**2.1 Background**

544

545 For over 40 y the linear nonthreshold (LNT) dose-response model has been used to develop practical and  
546 prudent guidance on ways to protect workers and the general public from the potential harmful effects of radiation  
547 while, at the same time, balancing the beneficial, justified, and optimized uses of radiation in our society. Indeed,  
548 in developing its basic radiation protection recommendations, as currently given in NCRP Report No. 116 (NCRP,  
549 1993a), the Council reiterated its acceptance of the LNT for the dose-risk relationship. Specifically, “based on the  
550 hypothesis that genetic effects and some cancers may result from damage to a single cell, the Council assumes  
551 that, for radiation-protection purposes, the risk of stochastic effects is proportional to dose without threshold,  
552 throughout the range of dose and dose rates of importance in routine radiation protection. Furthermore, the  
553 probability of response (risk) is assumed, for radiation protection purposes, to increase linearly with dose. At  
554 higher doses, received acutely, such as in accidents, more complex (nonlinear) dose/risk relationships may apply”  
555 (NCRP, 1993a).

556

557 NCRP later reassessed the weight of scientific evidence for and against the LNT model without reference to  
558 associated policy implications in Report No. 136 (NCRP, 2001). As in previous reviews by the NCRP (1980;  
559 1993c; 1997) the Council concluded that there was no conclusive evidence on which to reject the assumption of a  
560 LNT dose-response relationship for many of the risks attributable to low-level ionizing radiation (although it was  
561 acknowledged that additional data were needed) (NCRP, 1993b). The NCRP then noted that while many, but not  
562 all, scientific data support this assumption (NCRP, 1995), the probability of effects at very low doses such as are  
563 received from ubiquitous low-LET background radiation (NCRP, 1987; 2015) is so small that it may never be  
564 possible to prove or disprove the validity of the LNT assumption at those dose levels.

565

566 The International Commission on Radiological Protection (ICRP) published a science evaluation report,  
567 Publication 99 (ICRP, 2005b), on low-dose extrapolation of radiation-related cancer risks and issued updated  
568 radiation protection recommendations based on the conclusion that “while existence of a low dose threshold does  
569 not seem unlikely for radiation-related cancers of certain tissues, and cannot be ruled out for all cancers as a group,  
570 the evidence as a whole does not favor the existence of a universal threshold, and there seems to be no particular  
571 reason to factor the possibility of a threshold into risk calculations for purposes of radiation protection (ICRP,  
572 2007).” ICRP concluded that a LNT theory, combined with an uncertain DDREF for extrapolation of risk from high  
573 doses received acutely remains a prudent basis for radiation protection at low doses and low dose rates (ICRP,  
574 2005b).

575  
576 The United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) evaluates the  
577 evidence of radiation-induced health effects from studies of the health of survivors of the atomic bombings of  
578 Japan and of other exposed groups. It also reviews advances in understanding of the mechanisms by which  
579 radiation-induced health effects can occur. These assessments provide the scientific foundation used by the  
580 International Commission on Radiological Protection (ICRP) and other protection organizations in developing  
581 their recommendations on radiation protection. UNSCEAR has concluded that the simplest representation of  
582 tumorigenic response is a linear relationship, which is consistent with much of the available mechanistic and  
583 quantitative data and strongly supports the scientific rationale for the LNT model as used in radiation protection  
584 (UNSCEAR, 2000; 2006). A departure from linearity was noted for leukemia data, for which a linear-quadratic  
585 function was used. It was noted that linear or linear-quadratic functions are used for representational purposes only  
586 in evaluating possible radiation risks and that the actual response may involve multiple and competing processes  
587 that cannot be separately distinguished.

588  
589 Based on the available epidemiologic data, UNSCEAR derived risk estimates and noted, as a first  
590 approximation, linear extrapolation of the estimates at 1 Sv could be used for estimating solid cancer risks at lower  
591 doses. The rationale was re-evaluated in the UNSCEAR 2006 Report, Effects of Ionizing Radiation Vol. 1  
592 (UNSCEAR, 2008), that included several new cancer sites and used Bayesian methods for the incorporation of  
593 dose uncertainty in the atomic-bomb survivor cohort risk, and concluded that “the data reviewed for its 2006  
594 report do not necessitate changes in its current risk estimates for cancer and the hereditary effects of radiation.”  
595 However, this conclusion was based primarily on the LSS dose-response data following a high dose rate brief  
596 exposure and not on an evaluation of cancer excesses after exposure at low dose rates.

597  
598 The National Academies (NA) published the Biological Effects of Ionizing Radiation (BEIR) VII report  
599 (NA/NRC, 2006) that concluded that the available biological and biophysical data support a LNT risk model,  
600 whereby the risk of cancer proceeds in a linear fashion at lower doses without a threshold. The U.S. Environmental  
601 Protection Agency (EPA) in evaluating radiogenic risk models (EPA, 2011) noted that in general, results from  
602 epidemiologic and radiobiologic research are consistent with an LNT dose-response model in which the risk of  
603 inducing a cancer in an irradiated tissue by low doses of radiation is proportional to the dose to that tissue, while  
604 acknowledging that new research might conceivably lead to revisions in the future. In contrast, a report from the  
605 French Academy of Sciences (Tubiana *et al.*, 2005) that focused primarily on radiobiology raised doubts about the  
606 validity of using the LNT model for evaluating carcinogenic risks at low doses and suggested that since biological  
607 mechanisms and responses appear different at low doses and high doses, an empirical relationship of linearity  
608 validated at only doses >150 mSv may lead to an overestimation of risks at low doses.

609  
610 Box (1979) concluded that “all models are wrong but some are useful”. The LNT model is an assumption that  
611 has not been and likely cannot be scientifically validated in the low-dose range. Other dose-response relationships  
612 for the mutagenic and carcinogenic or detrimental effects of low-level radiation cannot be excluded, and there are  
613 notable exceptions to the LNT relationship seen in experimental and epidemiologic studies (Boice, 2015c; Dauer  
614 *et al.*, 2010). Nonetheless, on the basis of the scientific knowledge to date the current judgment by national and  
615 international scientific committees is that no alternative dose-response relationship currently appears more  
616 pragmatic or prudent for radiation protection purposes than the LNT model.

## 617 618 **2.2 LNT and the Estimation of Cancer Risk**

619  
620 As part of the process for developing nominal dose limits for radiation protection purposes, it is the current  
621 practice of ICRP, for example, to calculate total health detriment values for exposure to low doses and low dose  
622 rates of radiation (ICRP, 2007). Detriment values are based largely on the risk estimates for fatal cancers, nonfatal  
623 cancers and heritable effects (so-called stochastic effects) and also factors such as quality of life and adjustment for  
624 DDREF. Until recently, little consideration has been placed on noncancer effects (harmful tissue reactions,  
625 previously called deterministic effects) for the calculation of nominal risk, largely because it has been assumed that  
626 noncancer effects have quite large threshold responses and that cancer is dominant at low doses and low dose rates.  
627 This assumption is being reassessed, most specifically for cataracts and cardiovascular diseases (ICRP, 2012;  
628 NCRP, 2007). How to use this information, if indeed it is to be used, for noncancer responses in a detriment  
629 calculation remains a matter of scientific debate and clearly requires additional human data on radiation-induced  
630 adverse health outcomes.

631  
632 The process of estimating risks for adverse health outcomes (cancer and noncancer) has relied almost  
633 exclusively on the available human epidemiology data from exposed populations, in particular the survivors of  
634 the atomic bombs in Japan, but with additional support from other exposed populations, including those exposed  
635 occupationally, environmentally, or from medical diagnostic and treatment procedures. Rather little use of the  
636 extensive radiobiology data has been made in the risk assessment process, with the exception of calculations of  
637 the DDREF and radiation weighting factors.

638  
639 The general approach used by ICRP, EPA, NA/NRC (2006) and NCRP for cancer risk estimation used for  
640 protection purposes has been to develop a dose-response curve for all solid cancers assessed in the LSS  
641 following acute exposures that are highly influenced by the mid to high dose ranges and to extrapolate from this  
642 range to estimate cancer frequencies at low doses assuming no threshold, a LNT extrapolation. A DDREF is

643 applied to the slope of the linear extrapolation to estimate the cancer risk at low dose rates and often also for  
644 low doses. It is important to note that the use of an LNT extrapolation model is really a default approach  
645 because of a lack of definitive evidence to the contrary (Preston, 2003). Considerations of nonlinear  
646 extrapolations for solid cancer risk from high-to-moderate doses are continually being investigated and received  
647 some support from the recent studies on solid cancer incidence and mortality for the LSS (Grant *et al.*, 2017;  
648 Ozasa *et al.*, 2012).

649  
650 A number of uncertainties are associated with the current approach to apply the scientific evidence for  
651 radiation protection, especially for DDREF and also with the model chosen for extrapolation (LNT) (NCRP,  
652 2012). It is difficult to conduct epidemiology studies that will allow for direct measurement of adverse health  
653 outcomes at low doses and dose rates, although the ongoing Million Person Study (Boice, 2012a; 2017) can  
654 enhance the assessment at low doses and low dose rates. The way forward is most likely to include an integration  
655 of epidemiology and radiobiology data (NCRP, 2015).

656

### 657 **2.3 Objective and Scope**

658

659 This Commentary is to provide a review of recent data from new epidemiologic studies and data of  
660 populations exposed to radiation at low dose rates and to review the new data from the Life Span Study of atomic-  
661 bomb survivors. The purpose is to determine whether these epidemiologic studies broadly support the LNT model  
662 of carcinogenic risk as used in radiation protection or, on the contrary, whether there is sufficient evidence that the  
663 LNT model is inappropriate? The strength of support for the LNT model is evaluated for solid cancer incidence or  
664 mortality and secondarily for low dose-rate studies of leukemia. The focus is on new human studies on low doses  
665 and low dose rates. In addition, the report will briefly review current evidence regarding certain noncancer  
666 outcomes, such as cardiovascular diseases, and risk from childhood exposure and heritable radiation risk.

667

668 This Commentary was written by a committee of multi-disciplinary experts based on a comprehensive review  
669 of recent (within approximately 10 y) relevant epidemiologic studies, especially those that have been extensively  
670 studied, with attention paid to epidemiologic methodology, dosimetry and statistical approaches. The Committee  
671 performed a critical but balanced evaluation of these epidemiologic studies, including a description of their  
672 strengths and limitations, similar to the approach utilized in recent related reviews by UNSCEAR (2008; 2013).  
673 The present evaluation includes a detailed assessment of the dosimetric and statistical approaches employed for the  
674 epidemiologic study. The aim was to develop a perspective for each study and evaluate its strength with regard to  
675 radiation protection implications. Future directions and ongoing research needs were identified.

676